Daybreak Wake up, Neo. There’s a glitch in the pharma matrix
10 snips
Mar 18, 2026 A deep dive into how common medicines can carry astonishing markups, sometimes over 1,000%. The supply chain from manufacturer to pharmacist is unpacked to show why prices balloon. The story explores incentive stacks, distribution margins, and legal gaps that keep patients paying. It also looks at disruptors like Jan Aushadhi, e-pharmacies, and regulatory fixes that could shrink those spreads.
AI Snips
Chapters
Transcript
Episode notes
Pharmacist Choosing Price Over Patient
- A pharmacist (Morpheus) offers two identical acidity pills with wildly different prices at the counter.
- Aristo's strip left the factory at Rs 14 and sold for Rs 170, while Ajjan Aushadi Kendra sells the same dose for Rs 30, exposing the markup game.
MRP Is A Budget For Distribution Incentives
- The MRP reflects the distribution incentive stack, not the drug's manufacturing cost.
- Companies set high MRPs to fund downstream margins and promotions, creating 600–3,700% markups on generics.
Low-Stakes Drugs Carry The Highest Markups
- Many highest-markup drugs treat low-stakes, short-term conditions where patients don't comparison-shop.
- Categories like acidity, allergy, cough and supplements see 600–1,800% markups because of consumer price apathy.